Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3

NCT ID: NCT01868945

Last Updated: 2015-03-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

59 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the dose of Hy.D Calcifediol 25 SD/S (a metabolite of vitamin D3) which will achieve the range of mean serum 25(OH)D between 75-100nmol/L in physically frail elderly people after 24 weeks of daily supplementation with different doses of Hy.D Calcifediol 25 SD/S compared to vitamin D3.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-frail Elderly Frail Elderly

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

5 µg/day Hy.D Calcifediol

Group Type EXPERIMENTAL

5 µg/day Hy.D Calcifediol

Intervention Type DIETARY_SUPPLEMENT

5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks

10 µg/day Hy.D Calcifediol

Group Type EXPERIMENTAL

10 µg/day Hy.D Calcifediol

Intervention Type DIETARY_SUPPLEMENT

10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks

15 µg/day Hy.D Calcifediol

Group Type EXPERIMENTAL

15 µg/day Hy.D Calcifediol

Intervention Type DIETARY_SUPPLEMENT

15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks

20 µg/day vitamin D3

Group Type ACTIVE_COMPARATOR

20 µg/day vitamin D3

Intervention Type DIETARY_SUPPLEMENT

20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

5 µg/day Hy.D Calcifediol

5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks

Intervention Type DIETARY_SUPPLEMENT

10 µg/day Hy.D Calcifediol

10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks

Intervention Type DIETARY_SUPPLEMENT

15 µg/day Hy.D Calcifediol

15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks

Intervention Type DIETARY_SUPPLEMENT

20 µg/day vitamin D3

20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 25(OH)D levels between 25 - 50 nmol/L;
* Age 65 and older;
* Physically frail, based on the criteria designed by Fried et al. \[1\]. Frailty will be defined as a clinical syndrome in which one or more of the following criteria are present: unintentional weight loss (4.5 kg in past year), selfreported exhaustion (CES-D questionnaire), weakness (grip strength), slow walking speed and low physical activity (Minnesota questionnaire). These criteria are easily assessable and have been commonly used to determine frailty;
* Men and women;
* Body mass index between 20 and 35 kg/m2 (used for stratification);
* Willingness and ability to comply with the protocol.

Exclusion Criteria

* Medical Illness: malabsorption syndrome: known intestinal malabsorption, celiac diseases, inflammatory bowel disease; diseases that may enhance serum calcium concentration: sarcoidosis, lymphoma, kidney stone in the last 10 years, primary hyperparathyroidism; abnormal indices of calcium metabolism, uncontrolled hypocalcaemia; diagnosed renal insufficiency, diagnosed cancer, diagnosed liver failure.
* Hypercalcemia : serum calcium adjusted for albumin of \> 2.6 nmol/L.
* Medication: bisphosphonate or Parathyroid hormone (PTH) treatment, tuberculostatics, epilepsy medication, interfering with vitamin D metabolism and vitamin D supplementation.
* Use of vitamin D supplementation in the last three months (excluding multivitamin supplementation).
* Not willing to stop the use of multivitamin supplementation during the study.
* (Expected) increase in exposure to sunlight (e.g. travelling to a sunny resort).
* Patient heavily consumes alcohol containing products defined as greater than (\>) 3 drinks (beer, wine, or distilled spirits) of alcoholic beverages per day.
* Donating blood in the period of 2 months before, until 1 month after the end of the study.
* Planned surgery.
* Participation in another clinical trial.
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

DSM Nutritional Products, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lisette De Groot, Prof

Role: PRINCIPAL_INVESTIGATOR

Wageningen University

Michael Tieland, PhD

Role: PRINCIPAL_INVESTIGATOR

Wageningen University

Luc van Loon, Prof

Role: PRINCIPAL_INVESTIGATOR

Maastricht University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wageningen University

Wageningen, Wageningen, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Vaes AMM, Tieland M, de Regt MF, Wittwer J, van Loon LJC, de Groot LCPGM. Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults. Clin Nutr. 2018 Jun;37(3):808-814. doi: 10.1016/j.clnu.2017.03.029. Epub 2017 Mar 31.

Reference Type DERIVED
PMID: 28433267 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-10-24-HyD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Optimizing Vitamin D in the Elderly
NCT01554241 COMPLETED NA
Treatment of Vitamin D Insufficiency
NCT00933244 COMPLETED PHASE4
Finnish Vitamin D Trial (FIND)
NCT01463813 COMPLETED NA